Positive Phase II Results For FX06 - Fibrin-Derived Peptide For The Treatment Of Reperfusion Injury In Myocardial Infarction
September 7th, 2008 by 
admin Fibrex Medical, a biopharmaceutical consort centering on cardiovascular and inflammatory diseases, declared constructive Phase II results for FX06, a peptide for the communication of reperfusion trauma - the alteration to hunch hooligan that results from remedial communication mass a hunch attack. The results module be presented at the ESC legislature today in Munich, Germany. The Phase II clinical effort of FX06 (F.I.R.E.
Posted in Cardiology | 